Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 6/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27764951 | 0.82 | RXFP1 (0.43) | RXFP1MEN1KMT2AAHRPHGDH | |
| SCHEMBL4019147 | 0.80 | MAPT (0.49) | RXFP1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL1335436 | 0.79 | ALDH1A1 (0.54) | MEN1KMT2AKDM4EHCRTR1 | |
| SCHEMBL21803746 | 0.79 | MCL1 (0.54) | MAPTNPSR1 | |
| SCHEMBL12921152 | 0.79 | BRPF1 (0.56) | TDP1KDM4EMAPTCASP1CASP7 | |
| SCHEMBL18258146 | 0.78 | PTGER4 (0.54) | PTGER4TDP1KDM4EMAPT | |
| SCHEMBL7982455 | 0.76 | ALDH1A1 (0.56) | MEN1KMT2APTGER4KDM4EMAPT | |
| SCHEMBL342762 | 0.76 | GRIN2D (0.51) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL29894136 | 0.76 | GRIN2D (0.51) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL12958606 | 0.75 | ALB (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023115203-A1 | OXER1 ANTAGONISTS AND USES THEREOF | FAIRHAVEN PHARMACEUTICALS INC. (CA) | 2023-06-29 | — | — | WO | disclosed |
| CN-107635961-B | Indole analogs as 5-oxo-ETE receptor antagonists and methods of use thereof | 皇家学习促进学会/麦吉尔大学 | 2021-07-20 | — | — | CN | disclosed |
| US-10941162-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10919914-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3277665-B1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2020-03-04 | — | — | EP | disclosed |
| EP-3277665-B1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2020-03-04 | — | — | EP | disclosed |
| US-20190330240-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-03-29 | — | — | US | disclosed |
| WO-2016154749-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016154749-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-10-06 | — | — | WO | disclosed |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-05-05 | — | — | US | disclosed |
| WO-2016054491-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-07 | — | — | WO | disclosed |
| EP-1660464-B1 | CASPASE INHIBITORS CONTAINING ISOXAZOLINE RING | LG LIFE SCIENCES LTD (KR) | 2015-02-25 | — | — | EP | disclosed |
| CN-1842521-B | Caspase inhibitors containing isoxazoline ring | LG LIFE SCIENCES LTD | 2012-09-05 | — | — | CN | disclosed |
| US-7557133-B2 | Caspase inhibitors containing isoxazoline ring | LG LIFE SCIENCES LTD. (KR) | 2009-07-07 | — | — | US | disclosed |
| US-20060223848-A1 | Caspase inhibitors containing isoxazoline ring | LG CHEM, LTD. (KR) | 2006-10-05 | — | — | US | disclosed |
| CN-1842521-A | Caspase inhibitors containing isoxazoline ring | LG LIFE SCIENCES LTD (KR) | 2006-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919914-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | RXFP1 4131/4885MEN1 1386/4885KMT2A 3819/4885 |
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | HTR5A, EDNRA, HTR3E | RXFP1 219/4885MEN1 3985/4885KMT2A 3866/4885 |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | RXFP1 4131/4885MEN1 1386/4885KMT2A 3819/4885 |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | RXFP1 4131/4885MEN1 1386/4885KMT2A 3819/4885 |
| US-10941162-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | RXFP1 4536/4885MEN1 2006/4885KMT2A 3911/4885 |
| US-20190330240-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | RXFP1 4131/4885MEN1 1386/4885KMT2A 3819/4885 |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | RXFP1 4144/4885MEN1 1188/4885KMT2A 3671/4885 |
| US-20060223848-A1 | Caspase inhibitors containing isoxazoline ring | CASP1, CASP7, CASP2 | RXFP1 3080/4885MEN1 4843/4885KMT2A 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.